1. Mechanism and spectrum of action, side effects, contraindications and indications for prescribing drugs for arrhythmia (I class). Interaction 2. contraindications and Mechanism and spectrum of action, side effects, indications for prescribing anticoagulants. Interaction. Give me a correct answer in short
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I have comprehensive content from Lippincott Pharmacology on both topics. Let me now compile the full answer.
Class I Antiarrhythmic Drugs (Na⁺ Channel Blockers)
Mechanism of Action
Class I drugs block fast inward Na⁺ channels, reducing the rate of rise of phase 0 of the action potential. This slows conduction velocity and suppresses abnormal automaticity. They also prevent reentry by converting unidirectional block into bidirectional block.
Subdivided by kinetics and effects on action potential duration (APD):
| Subclass | Drugs | Na⁺ Block Kinetics | Effect on APD / QT |
|---|---|---|---|
| IA | Quinidine, Procainamide, Disopyramide | Intermediate | Prolongs (also blocks K⁺ channels) |
| IB | Lidocaine, Mexiletine | Fast (weak block) | Shortens |
| IC | Flecainide, Propafenone | Slow (potent block) | No change |
Class IA (Quinidine, Procainamide, Disopyramide)
Mechanism
- Block Na⁺ channels + K⁺ channels → slow conduction + prolong refractory period + widen QRS + prolong QT.
- Quinidine also has anticholinergic and α-blocking effects.
Spectrum / Indications
- Supraventricular tachycardias (SVT), atrial flutter/fibrillation (conversion & maintenance), ventricular tachycardia (VT), Wolff-Parkinson-White (WPW) syndrome.
Side Effects
- Quinidine: diarrhea, nausea, cinchonism (tinnitus, headache), thrombocytopenia, torsades de pointes, QT prolongation, α-blockade (hypotension).
- Procainamide: lupus-like syndrome (long-term), agranulocytosis, hypotension (IV), torsades de pointes.
- Disopyramide: anticholinergic effects (urinary retention, dry mouth, constipation, blurred vision), negative inotropy → heart failure.
Contraindications
- Heart failure (especially disopyramide — strong negative inotrope).
- Prolonged QT, torsades de pointes history.
- Complete heart block, myasthenia gravis (disopyramide).
- Procainamide: avoid in lupus patients.
Interactions
- Quinidine + digoxin → raises digoxin levels (toxicity risk).
- All Class IA: additive QT prolongation with other QT-prolonging drugs (macrolides, antipsychotics).
- Anticholinergic drugs amplify disopyramide side effects.
Class IB (Lidocaine, Mexiletine)
Mechanism
- Preferentially bind inactivated Na⁺ channels in ischemic/depolarized tissue → shorten APD and refractory period → suppress ventricular ectopy.
- Minimal effect on normal atrial tissue.
Spectrum / Indications
- Ventricular arrhythmias only (VT, VF) — especially in acute MI setting.
- Lidocaine: IV, acute ventricular arrhythmias (second-line after amiodarone).
- Mexiletine: oral, chronic ventricular arrhythmias, long QT syndrome type 3 (adjunct).
Side Effects
- CNS: dizziness, confusion, paresthesias, seizures (especially lidocaine at high doses).
- Cardiovascular: minimal at therapeutic doses.
Contraindications
- Lidocaine: hypersensitivity to amide local anesthetics, severe hepatic disease, Stokes-Adams syndrome.
- Not effective for atrial arrhythmias.
Interactions
- Cimetidine/propranolol → ↓ hepatic clearance of lidocaine → toxicity.
Class IC (Flecainide, Propafenone)
Mechanism
- Potent Na⁺ channel blockade → markedly slow conduction, widen QRS, minimal effect on APD.
- Propafenone also has mild β-blocking activity.
Spectrum / Indications
- SVT, atrial fibrillation/flutter (especially paroxysmal AF in structurally normal hearts — "pill in pocket").
- WPW syndrome.
- Not used post-MI or in structural heart disease (CAST trial: increased mortality).
Side Effects
- Proarrhythmic (most dangerous of class I) — can cause VT/VF.
- Flecainide: visual disturbances, dizziness.
- Propafenone: metallic taste, bronchospasm (β-block), nausea.
Contraindications
- Post-MI, structural heart disease, LV dysfunction — absolute contraindications.
- Propafenone: asthma/COPD (β-blocking effect).
Interactions
- Flecainide: digoxin levels ↑.
- Propafenone: ↑ warfarin effect, ↑ digoxin levels.
- CYP2D6 inhibitors (fluoxetine, paroxetine) ↑ levels of both drugs.
Anticoagulants
Mechanism of Action
1. Unfractionated Heparin (UFH)
- Binds antithrombin III (AT-III) → conformational change → AT-III inhibits thrombin (IIa), Xa, IXa, XIa, XIIa (primarily IIa and Xa).
- Acts immediately; given IV or SC; monitored by aPTT.
- Reversible with protamine sulfate.
2. Low-Molecular-Weight Heparins (LMWH) — Enoxaparin, Dalteparin
- Preferentially inhibit factor Xa (less anti-IIa activity) via AT-III.
- More predictable pharmacokinetics → weight-based SC dosing; monitored by anti-Xa levels.
- Partially reversible with protamine.
3. Fondaparinux
- Synthetic pentasaccharide; selectively inhibits factor Xa via AT-III.
- Not reversible by protamine; no direct anti-IIa activity.
4. Warfarin (Oral)
- Inhibits vitamin K epoxide reductase (VKORC1) → prevents regeneration of active vitamin K → impairs synthesis of clotting factors II, VII, IX, X (and anticoagulant proteins C, S).
- Delayed onset (~5 days); monitored by INR (target 2–3 typically).
- Reversed by vitamin K, FFP, or prothrombin complex concentrate (PCC).
5. Direct Oral Anticoagulants (DOACs)
| Drug | Target | Monitoring |
|---|---|---|
| Dabigatran | Direct thrombin inhibitor (IIa) | aPTT (qualitative) |
| Rivaroxaban, Apixaban, Edoxaban | Direct factor Xa inhibitors | Anti-Xa (if needed) |
6. Direct Thrombin Inhibitors (Parenteral) — Argatroban, Bivalirudin
- Directly inhibit thrombin without AT-III; used in heparin-induced thrombocytopenia (HIT).
Indications
| Drug | Main Indications |
|---|---|
| UFH | Acute DVT/PE, ACS, cardiopulmonary bypass, bridging therapy |
| LMWH | DVT/PE treatment & prophylaxis, ACS, pregnancy (preferred over warfarin) |
| Fondaparinux | DVT/PE prophylaxis & treatment, HIT (no cross-reactivity) |
| Warfarin | AF (stroke prevention), mechanical heart valves, DVT/PE long-term, antiphospholipid syndrome |
| DOACs | AF (non-valvular), DVT/PE treatment & prevention |
| Argatroban/Bivalirudin | HIT, PCI in HIT patients |
Side Effects
| Drug | Key Side Effects |
|---|---|
| Heparin (UFH) | HIT (immune-mediated thrombocytopenia + paradoxical thrombosis), bleeding, osteoporosis (long-term), hyperkalemia |
| LMWH | Bleeding, less HIT than UFH, osteoporosis (less) |
| Warfarin | Bleeding, skin necrosis (protein C/S deficiency at initiation), teratogenicity (crosses placenta), drug interactions |
| DOACs | Bleeding; dabigatran — GI upset, dyspepsia |
| Fondaparinux | Bleeding; accumulates in renal failure |
Contraindications
| Drug | Key Contraindications |
|---|---|
| All anticoagulants | Active major bleeding, recent CNS surgery/hemorrhage, hemorrhagic stroke, severe thrombocytopenia |
| Heparin | Prior HIT (absolute CI — switch to argatroban/bivalirudin) |
| Warfarin | Pregnancy (teratogen — risk of embryopathy weeks 6–12, fetal CNS/bleeding); severe hepatic disease |
| LMWH / Fondaparinux | Severe renal failure (CrCl <30 mL/min) — accumulation and bleeding risk |
| DOACs | Mechanical heart valves (dabigatran proven harmful), severe renal failure (varies by drug), pregnancy |
Drug Interactions
Warfarin (most interactions)
- ↑ anticoagulant effect (bleeding risk): amiodarone, metronidazole, fluconazole, ciprofloxacin, omeprazole, aspirin, NSAIDs, broad-spectrum antibiotics (↓ gut flora → ↓ vitamin K).
- ↓ anticoagulant effect (thrombosis risk): rifampicin, carbamazepine, phenytoin, barbiturates (CYP450 inducers); vitamin K-rich foods (green leafy vegetables).
Heparin
- Additive bleeding with: antiplatelet drugs (aspirin, clopidogrel), thrombolytics, NSAIDs.
- Protamine sulfate = antidote.
DOACs
- P-glycoprotein and CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) → ↑ DOAC levels.
- Rifampicin, carbamazepine → ↓ DOAC levels.
- No routine dietary interactions (unlike warfarin).
Sources: Lippincott Illustrated Reviews: Pharmacology; Katzung's Basic and Clinical Pharmacology 16E; Harrison's Principles of Internal Medicine 22E
CHOOSING A MEDICINE FOR A SPECIFIC CLINICAL SITUATION Case 10: Patient E. 48 years old. Complaints of headaches of a pressing nature, an increase in blood pressure to 180 mmHg, compressive pains in the heart and behind the sternum that occur during physical exertion, attacks of suffocation 2-3 times a month, cough with difficult-to-separate sputum. From anamnesis: hypertension, coronary heart disease, asthma for many years. Objectively: the condition is of moderate severity, consciousness is clear. BP is 165/100 mmHg; heart rate is 52 per minute; Auscultation heart tones are muted, the rhythm is correct. In the lungs, breathing is vesicular, with occasional dry wheezing. There is no peripheral edema. ECG: sinus rhythm with a heart rate of 54 beats per minute. Hypertrophy of the left ventricle. Scar fields on the posterior wall of the left ventricle. Choose an antihypertensive drug Station 1 1. Identify the problem (diagnosis): 2. Choose your P-medication for this condition: 3. Dosage form 4. Dosage Station 2 5. Pharmacokinetics of the drug 6. Mechanism of action 7. Write a prescription Station 3 8. Duration of treatment 9. Side effects 10. Contraindications
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
I have sufficient information. Here is the complete structured answer:
Case 10 — Clinical Pharmacology Answer
Station 1
1. Diagnosis (Problem Identification)
Combined diagnosis:
- Hypertensive disease, Stage III, Grade 2 (BP 165/100 mmHg; target organ damage — LV hypertrophy, post-MI scar)
- Coronary artery disease (CAD): Stable angina pectoris (exertional compressive chest pain; posterior LV scar on ECG)
- Bronchial asthma (episodic dyspnea 2–3×/month, dry wheezing, productive cough)
- Bradycardia (HR 52–54 bpm)
Key therapeutic challenge: The patient has indications for antihypertensives AND antianginals, but β-blockers are contraindicated (asthma + bradycardia), and ACE inhibitors are relatively contraindicated (asthma — ACE inhibitor cough may worsen bronchospasm).
2. Drug of Choice — P-medication
Amlodipine (Dihydropyridine calcium channel blocker)
Rationale:
- Controls hypertension ✓
- Relieves stable angina (reduces afterload + coronary vasodilation) ✓
- Safe in asthma — no bronchospasm risk ✓
- Does not lower heart rate (unlike verapamil/diltiazem) → safe with existing bradycardia ✓
- Proven cardiovascular outcome benefit post-MI ✓
β-blockers are contraindicated (asthma, bradycardia). Verapamil/diltiazem are contraindicated (bradycardia — they are negative chronotropic). ACE inhibitors should be avoided (ACE cough triggers bronchospasm in asthma).
3. Dosage Form
Tablet — 5 mg or 10 mg for oral administration.
4. Dosage
- Starting dose: 5 mg once daily
- Maintenance dose: 5–10 mg once daily (titrate after 7–14 days based on BP response)
- Maximum dose: 10 mg/day
Station 2
5. Pharmacokinetics
| Parameter | Value |
|---|---|
| Route | Oral |
| Bioavailability | ~64–90% |
| Tmax | 6–12 hours |
| Protein binding | ~98% (albumin) |
| Metabolism | Hepatic (CYP3A4) → inactive metabolites |
| Half-life (t½) | 35–50 hours (allows once-daily dosing) |
| Elimination | Urine (~60% as metabolites) |
| Onset of action | Gradual (no reflex tachycardia due to slow onset) |
Long t½ ensures smooth 24-hour BP control without peaks and troughs.
6. Mechanism of Action
Amlodipine is a dihydropyridine (DHP) calcium channel blocker. It selectively binds to voltage-gated L-type (slow) Ca²⁺ channels in vascular smooth muscle and cardiac cells.
- In vascular smooth muscle: blocks Ca²⁺ influx → vasodilation of arterioles → ↓ peripheral vascular resistance → ↓ BP (afterload reduction).
- In coronary arteries: dilates coronary vessels → ↑ oxygen supply to myocardium → relieves angina.
- In the heart: at therapeutic doses, minimal negative chronotropic/inotropic effect (DHP selectivity for smooth muscle over myocardium) → does not worsen bradycardia.
- Overall: reduces cardiac workload (↓ afterload), improves myocardial oxygen balance.
7. Prescription
Rp.: Amlodipini 5 mg
D.t.d. N. 30 in tab.
S. Take 1 tablet (5 mg) once daily, orally, in the morning.
(After 2 weeks, increase to 10 mg/day if BP remains >140/90 mmHg)
Station 3
8. Duration of Treatment
Lifelong (indefinitely).
Amlodipine is prescribed for chronic management of hypertension and stable angina. Abrupt discontinuation may cause rebound angina. The dose is adjusted, not stopped, based on clinical response.
9. Side Effects
| System | Side Effects |
|---|---|
| Cardiovascular | Peripheral edema (ankle/pedal) — most common; flushing; palpitations; reflex tachycardia (less with amlodipine vs. short-acting DHPs) |
| CNS | Headache, dizziness |
| GI | Nausea, abdominal discomfort |
| Skin | Flushing |
| Gingival | Gingival hyperplasia (long-term) |
| Serious | Severe hypotension (overdose); worsening heart failure (rare — less than with other CCBs) |
Peripheral edema is due to precapillary vasodilation without corresponding venodilation — not fluid retention.
10. Contraindications
| Contraindication | Reason |
|---|---|
| Severe hypotension (SBP <90 mmHg) | Risk of circulatory collapse |
| Cardiogenic shock | Cannot tolerate vasodilation |
| Severe aortic stenosis | Fixed outflow obstruction — vasodilation dangerous |
| Unstable angina / acute MI (short-acting DHPs) | Reflex tachycardia risk (not an issue with amlodipine) |
| Hypersensitivity to dihydropyridines | Allergic reactions |
| Pregnancy (relative) | Fetal safety not fully established |
In this patient's case: Amlodipine has no contraindications — it is specifically the drug of choice precisely because β-blockers, diltiazem, verapamil, and ACE inhibitors are all contraindicated or problematic.
Sources: Katzung's Basic and Clinical Pharmacology 16E; Goldman-Cecil Medicine; Lippincott Illustrated Reviews: Pharmacology
Give me a short correct answer
Case 10 — Short Answer
Station 1
1. Diagnosis:
Hypertension Stage III + Stable angina (CAD, post-MI) + Bronchial asthma + Bradycardia (HR 52/min)
2. P-drug: Amlodipine
- Lowers BP ✓, relieves angina ✓, safe in asthma ✓, does not slow HR ✓
- β-blockers contraindicated (asthma + bradycardia); ACE inhibitors avoided (cough → bronchospasm); verapamil/diltiazem contraindicated (bradycardia)
3. Dosage form: Tablet 5 mg / 10 mg
4. Dose: 5 mg once daily → titrate to 10 mg/day if needed
Station 2
5. Pharmacokinetics:
- Oral; bioavailability ~65–90%; t½ = 35–50 h (once daily); hepatic metabolism (CYP3A4); renal excretion
6. Mechanism:
Blocks L-type Ca²⁺ channels in vascular smooth muscle → arterial vasodilation → ↓ BP + ↓ afterload + coronary vasodilation → ↓ angina. Minimal cardiac depression (no bradycardia risk).
7. Prescription:
Rp.: Amlodipini 5 mg
D.t.d. N. 30 in tab.
S. 1 tab. once daily, orally, morning.
Station 3
8. Duration: Lifelong (chronic disease)
9. Side effects: Peripheral edema (most common), flushing, headache, dizziness, gingival hyperplasia
10. Contraindications: Severe hypotension, cardiogenic shock, severe aortic stenosis, hypersensitivity to dihydropyridines
This is a shared conversation. Sign in to Orris to start your own chat.